Novavax, Inc. (NVAX) trades at a trailing P/E of 3.1, forward P/E of 32.5. Trailing earnings yield is 32.48%, forward earnings yield 3.08%. PEG 0.38 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 81/100 with 6/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.2 | -0.02 | -61.52 | 22.22 | - |
| 2017 | -2.0 | 0.05 | -3.57 | 11.64 | - |
| 2018 | -3.7 | 0.18 | -4.05 | 19.84 | - |
| 2019 | -0.7 | 0.02 | -0.52 | 5.14 | - |
| 2020 | -15.3 | -0.41 | 10.23 | 286.66 | - |
| 2021 | -6.1 | -0.03 | -30.27 | 53.87 | - |
| 2022 | -1.2 | 0.02 | -1.27 | 0.50 | - |
| 2023 | -0.9 | 0.02 | -0.67 | 0.87 | - |
| 2024 | -6.5 | 0.08 | -1.96 | 1.79 | - |
| 2025 | 2.5 | -0.01 | -8.52 | 0.97 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-20.68 | $15.35M | $-279.97M | -1823.5% |
| 2017 | $-12.56 | $31.18M | $-183.77M | -589.5% |
| 2018 | $-9.99 | $34.29M | $-184.75M | -538.8% |
| 2019 | $-5.40 | $18.66M | $-130.1M | -697.1% |
| 2020 | $-7.43 | $475.6M | $-427.51M | -89.9% |
| 2021 | $-23.44 | $1.15B | $-1.74B | -152.1% |
| 2022 | $-8.42 | $1.6B | $-657.94M | -41.1% |
| 2023 | $-5.41 | $556.38M | $-545.06M | -98% |
| 2024 | $-1.23 | $682.16M | $-187.5M | -27.5% |
| 2025 | $2.54 | $1.12B | $440.3M | 39.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.36 | $-6.16 – $8.88 | $399.79M | $310.2M – $448.42M | 8 |
| 2027 | $-0.33 | $-0.79 – $-0.09 | $254.48M | $117.86M – $331.42M | 7 |
| 2028 | $0.26 | $-0.52 – $0.97 | $350.42M | $344.66M – $356.18M | 5 |
| 2029 | $0.33 | $0.16 – $0.48 | $352.52M | $213.88M – $475.19M | 1 |
| 2030 | $0.90 | $0.44 – $1.30 | $453.89M | $275.39M – $611.83M | 1 |
